多嚢胞性卵巣症候群(PCOS)治療の世界市場研究

• 英文タイトル:Market Study on Polycystic Ovary Syndrome (PCOS) Treatment: Market Driven by Rising Prevalence of Endocrine Diseases

Market Study on Polycystic Ovary Syndrome (PCOS) Treatment: Market Driven by Rising Prevalence of Endocrine Diseases「多嚢胞性卵巣症候群(PCOS)治療の世界市場研究」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2301E004
• 出版社/出版日:Persistence Market Research / 2022年10月19日
• レポート形態:英文、PDF、306ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥735,000 (USD4,900)▷ お問い合わせ
  Site Licence¥1,140,000 (USD7,600)▷ お問い合わせ
  Enterprisewide¥1,590,000 (USD10,600)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Persistence Market Research社の本調査レポートは、世界の多嚢胞性卵巣症候群(PCOS)治療市場の現状について調査しています。本レポートでは、エグゼクティブサマリー、市場概要、主要市場動向、主要成功要因、市場背景、新型コロナウイルス感染症危機分析、需要分析・予測、治療薬クラス別(経口避妊薬、インスリン抵抗性改善薬、抗うつ剤、オルニチン脱炭酸酵素阻害剤、その他)分析、流通チャネル別(病院薬局、ドラッグストア/OTC、Eコマース、診療所)分析、地域別(北米、中南米、ヨーロッパ、東アジア、南アジア、オセアニア、中東・アフリカ)分析、構造分析、競争分析などをまとめております。本レポートには、Novartis AG、Sanofi.、Teva Pharmaceutical Industries Limited、Merck & Co., Inc. (Merck group)、AstraZeneca plc、Bayer AG、Abbott、Pfizer, Inc.、Bristol-Myer Squibb Companyなどの企業情報が含まれています。
・エグゼクティブサマリー
・市場概要
・主要市場動向
・主要成功要因
・市場背景
・新型コロナウイルス感染症危機分析
・需要分析・予測
・世界の多嚢胞性卵巣症候群(PCOS)治療市場規模:治療薬クラス別
- 経口避妊薬における市場規模
- インスリン抵抗性改善薬における市場規模
- 抗うつ剤における市場規模
- オルニチン脱炭酸酵素阻害剤における市場規模
- その他における市場規模
・世界の多嚢胞性卵巣症候群(PCOS)治療市場規模:流通チャネル別
-病院薬局チャネルの市場規模
- ドラッグストア/OTCチャネルの市場規模
- Eコマースチャネルの市場規模
- 診療所チャネルの市場規模
・世界の多嚢胞性卵巣症候群(PCOS)治療市場規模:地域別
- 北米の多嚢胞性卵巣症候群(PCOS)治療市場規模
- 中南米の多嚢胞性卵巣症候群(PCOS)治療市場規模
- ヨーロッパの多嚢胞性卵巣症候群(PCOS)治療市場規模
- 東アジアの多嚢胞性卵巣症候群(PCOS)治療市場規模
- 南アジアの多嚢胞性卵巣症候群(PCOS)治療市場規模
- オセアニアの多嚢胞性卵巣症候群(PCOS)治療市場規模
- 中東・アフリカの多嚢胞性卵巣症候群(PCOS)治療市場規模
・構造分析
・競争分析

Polycystic Ovary Syndrome (PCOS) Treatment Market: Scope of Report

The latest publication by Persistence Market Research on the global polycystic ovary syndrome (PCOS) treatment market evaluates the opportunities and current market landscape and provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights into current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2022-2032.

Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research’s study. This research study can support readers to know the demand for polycystic ovary syndrome treatment market products and the quantitative development opportunities during the study period.

The research is beneficial for shareholders in the landscape, including investors, product manufacturers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the polycystic ovary syndrome (PCOS) treatment market. Insights and information presented in this Persistence Market Research study can be leveraged by shareholders in the polycystic ovary syndrome treatment market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.

Market statistics, as well as information linked to the macro- as well as macroeconomic variables affecting the business scenario in the polycystic ovary syndrome treatment market, are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.

Key Market Segments

Persistence Market Research’s study on the polycystic ovary syndrome treatment market offers information divided into three important segments – drug class and distribution channel and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Drug Class

Oral Contraceptives
Insulin Sensitizing Agents
Antidepressants
Ornithine Decarboxylase Inhibitors
Aromatase Inhibitors & SERMs
Diuretics
Distribution Channel

Hospital Pharmacies
Drug Stores/OTC
e-Commerce
Clinics
Region

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East and Africa
Key Questions Answered in Report

Which regions will continue to remain the most profitable markets for PCOS treatment over the coming years?
How will changing trends impact the market?
How has the COVID-19 crisis impacted market growth?
How can market players capture the low-hanging opportunities in developed regions?
What are the strategies of stakeholders in the market to shape their position in this landscape?
What are the restraining factors that investors need to be aware of and might tackle while investing in the market?
What are the developmental trends that will impact the market?
How can companies in the polycystic ovary syndrome treatment market avail themselves of the growth opportunities in developed and emerging sectors?
Research Methodology

In Persistence Market Research’s study, a unique research methodology is utilized to conduct extensive research on the growth of the PCOS treatment market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts to ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market and makes Persistence Market Research’s projections on the growth prospects of the PCOS treatment market are more accurate and reliable.

レポート目次

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions & Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Innovation / Development Trends

4. Key Success Factors

    4.1. Product Adoption / Usage Analysis

    4.2. Regulatory Scenario

    4.3. Go-To-Market Strategy

    4.4. PESTLE Analysis

    4.5. Porters Analysis

    4.6. Supply Chain Analysis

    4.7. Impact of PCOS on the Quality of Life in Women in correlation to Age, BMI, Education, Work Place as well as Pregnancy

    4.8. A detailed Assessment of Healthcare Related Economic Burden of PCOS and Immediate & Long Term Impact

    4.9. Polycystic Ovary Syndrome (PCOS) Treatment Market: Payer Mix Assessment

    4.10. Treatment Options in Management of PCOS

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global GDP Growth Outlook

        5.1.2. Global Healthcare Expenditure

    5.2. Forecast Factors – Relevance & Impact

        5.2.1. Increasing Uses of Epilatory Therapy

        5.2.2. Growing Prevalence of PCOS

        5.2.3. Growing number of Manufacturing Companies

        5.2.4. Increasing awareness

        5.2.5. Side Effects of Symptomatic Treatment Drugs

        5.2.6. Strategic Mergers and Acquisitions Among Pharmaceutical Companies

    5.3. Market Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

    6.1. Current COVID19 Statistics and Probable Future Impact

    6.2. Current GDP Projection and Probable Impact

    6.3. COVID19 and Impact Analysis

    6.4. 2021 Market Scenario

    6.5. Recovery Scenario – Short term, Midterm and Long Term Impact

7. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Demand (in Value or Size in US$ Mn) Analysis 2015–2021 and Forecast, 2022–2032

    7.1. Historical Market Value (US$ Mn) Analysis, 2015–2021

    7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Analysis 2015–2021 and Forecast 2022–2032, By Drug Class

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis By Drug Class, 2015–2021

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2022–2032

        8.3.1. Oral contraceptives

        8.3.2. Insulin Sensitizing Agents

        8.3.3. Anti-Depressants

        8.3.4. Ornithine Decarboxylase Inhibitors

        8.3.5. Aromatase Inhibitors

        8.3.6. Diuretics

    8.4. Market Attractiveness Analysis By Drug Class

9. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Analysis 2015–2021 and Forecast 2022–2032, By Distribution Channel

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2015–2021

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2022–2032

        9.3.1. Hospital pharmacies

        9.3.2. Drug Stores/OTC

        9.3.3. E-commerce

        9.3.4. Clinics

    9.4. Market Attractiveness Analysis By Distribution Channel

10. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Analysis 2015–2021 and Forecast 2022–2032, by Region

    10.1. Introduction

    10.2. Historical Market Size (US$ Mn) Analysis, By Region, 2015–2021

    10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2022–2032

        10.3.1. North America

        10.3.2. Latin America

        10.3.3. Europe

        10.3.4. East Asia

        10.3.5. South Asia

        10.3.6. Oceania

        10.3.7. Middle East and Africa (MEA)

    10.4. Market Attractiveness Analysis By Region

11. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Analysis 2015–2021 and Forecast 2022–2032

    11.1. Introduction

    11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2021

    11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032

        11.3.1. By Country

            11.3.1.1. U.S.

            11.3.1.2. Canada

        11.3.2. By Drug Class

        11.3.3. By Distribution Channel

    11.4. Market Attractiveness Analysis

        11.4.1. By Country

        11.4.2. By Drug Class

        11.4.3. By Distribution Channel

    11.5. Drivers and Restraints – Impact Analysis

    11.6. Country Level Analysis & Forecast

        11.6.1. U.S. Polycystic Ovary Syndrome (PCOS) Treatment Market

            11.6.1.1. Introduction

            11.6.1.2. Market Analysis and Forecast by Market Taxonomy

                11.6.1.2.1. By Drug Class

                11.6.1.2.2. By Distribution Channel

        11.6.2. Canada Polycystic Ovary Syndrome (PCOS) Treatment Market

            11.6.2.1. Introduction

            11.6.2.2. Market Analysis and Forecast by Market Taxonomy

                11.6.2.2.1. By Drug Class

                11.6.2.2.2. By Distribution Channel

12. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market Analysis 2015–2021 and Forecast 2022–2032

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2021

    12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032

        12.3.1. By Country

            12.3.1.1. Brazil

            12.3.1.2. Mexico

            12.3.1.3. Rest of Latin America

        12.3.2. By Drug Class

        12.3.3. By Distribution Channel

    12.4. Market Attractiveness Analysis

        12.4.1. By Country

        12.4.2. By Drug Class

        12.4.3. By Distribution Channel

    12.5. Drivers and Restraints – Impact Analysis

    12.6. Country Level Analysis & Forecast

        12.6.1. Brazil Polycystic Ovary Syndrome (PCOS) Treatment Market

            12.6.1.1. Introduction

            12.6.1.2. Market Analysis and Forecast by Market Taxonomy

                12.6.1.2.1. By Drug Class

                12.6.1.2.2. By Distribution Channel

        12.6.2. Argentina Polycystic Ovary Syndrome (PCOS) Treatment Market

            12.6.2.1. Introduction

            12.6.2.2. Market Analysis and Forecast by Market Taxonomy

                12.6.2.2.1. By Drug Class

                12.6.2.2.2. By Distribution Channel

        12.6.3. Mexico Polycystic Ovary Syndrome (PCOS) Treatment Market

            12.6.3.1. Introduction

            12.6.3.2. Market Analysis and Forecast by Market Taxonomy

                12.6.3.2.1. By Drug Class

                12.6.3.2.2. By Distribution Channel

13. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market Analysis 2015–2021 and Forecast 2022–2032

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2021

    13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032

        13.3.1. By Country

            13.3.1.1. Germany

            13.3.1.2. Italy

            13.3.1.3. France

            13.3.1.4. U.K.

            13.3.1.5. Spain

            13.3.1.6. BENELUX

            13.3.1.7. Russia

            13.3.1.8. Rest of Europe

        13.3.2. By Drug Class

        13.3.3. By Distribution Channel

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Drug Class

        13.4.3. By Distribution Channel

    13.5. Drivers and Restraints – Impact Analysis

    13.6. Country Level Analysis & Forecast

        13.6.1. Germany Polycystic Ovary Syndrome (PCOS) Treatment Market

            13.6.1.1. Introduction

            13.6.1.2. Market Analysis and Forecast by Market Taxonomy

                13.6.1.2.1. By Drug Class

                13.6.1.2.2. By Distribution Channel

        13.6.2. France Polycystic Ovary Syndrome (PCOS) Treatment Market

            13.6.2.1. Introduction

            13.6.2.2. Market Analysis and Forecast by Market Taxonomy

                13.6.2.2.1. By Drug Class

                13.6.2.2.2. By Distribution Channel

        13.6.3. Italy Polycystic Ovary Syndrome (PCOS) Treatment Market

            13.6.3.1. Introduction

            13.6.3.2. Market Analysis and Forecast by Market Taxonomy

                13.6.3.2.1. By Drug Class

                13.6.3.2.2. By Distribution Channel

        13.6.4. Spain Polycystic Ovary Syndrome (PCOS) Treatment Market

            13.6.4.1. Introduction

            13.6.4.2. Market Analysis and Forecast by Market Taxonomy

                13.6.4.2.1. By Drug Class

                13.6.4.2.2. By Distribution Channel

        13.6.5. U.K. Polycystic Ovary Syndrome (PCOS) Treatment Market

            13.6.5.1. Introduction

            13.6.5.2. Market Analysis and Forecast by Market Taxonomy

                13.6.5.2.1. By Drug Class

                13.6.5.2.2. By Distribution Channel

        13.6.6. Benelux Union Polycystic Ovary Syndrome (PCOS) Treatment Market

            13.6.6.1. Introduction

            13.6.6.2. Market Analysis and Forecast by Market Taxonomy

                13.6.6.2.1. By Drug Class

                13.6.6.2.2. By Distribution Channel

        13.6.7. Nordic Countries Polycystic Ovary Syndrome (PCOS) Treatment Market

            13.6.7.1. Introduction

            13.6.7.2. Market Analysis and Forecast by Market Taxonomy

                13.6.7.2.1. By Drug Class

                13.6.7.2.2. By Distribution Channel

        13.6.8. Switzerland Polycystic Ovary Syndrome (PCOS) Treatment Market

            13.6.8.1. Introduction

            13.6.8.2. Market Analysis and Forecast by Market Taxonomy

                13.6.8.2.1. By Drug Class

                13.6.8.2.2. By Distribution Channel

        13.6.9. Russia Polycystic Ovary Syndrome (PCOS) Treatment Market

            13.6.9.1. Introduction

            13.6.9.2. Market Analysis and Forecast by Market Taxonomy

                13.6.9.2.1. By Drug Class

                13.6.9.2.2. By Distribution Channel

14. South Asia Polycystic Ovary Syndrome (PCOS) Treatment Market Analysis 2015–2021 and Forecast 2022–2032

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2021

    14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032

        14.3.1. By Country

            14.3.1.1. India

            14.3.1.2. Thailand

            14.3.1.3. Indonesia

            14.3.1.4. Malaysia

            14.3.1.5. Rest of South Asia

        14.3.2. By Drug Class

        14.3.3. By Distribution Channel

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Drug Class

        14.4.3. By Distribution Channel

    14.5. Drivers and Restraints – Impact Analysis

    14.6. Country Level Analysis & Forecast

        14.6.1. India Polycystic Ovary Syndrome (PCOS) Treatment Market

            14.6.1.1. Introduction

            14.6.1.2. Market Analysis and Forecast by Market Taxonomy

                14.6.1.2.1. By Drug Class

                14.6.1.2.2. By Distribution Channel

        14.6.2. Indonesia Polycystic Ovary Syndrome (PCOS) Treatment Market

            14.6.2.1. Introduction

            14.6.2.2. Market Analysis and Forecast by Market Taxonomy

                14.6.2.2.1. By Drug Class

                14.6.2.2.2. By Distribution Channel

        14.6.3. Malaysia Polycystic Ovary Syndrome (PCOS) Treatment Market

            14.6.3.1. Introduction

            14.6.3.2. Market Analysis and Forecast by Market Taxonomy

                14.6.3.2.1. By Drug Class

                14.6.3.2.2. By Distribution Channel

        14.6.4. Thailand Polycystic Ovary Syndrome (PCOS) Treatment Market

            14.6.4.1. Introduction

            14.6.4.2. Market Analysis and Forecast by Market Taxonomy

                14.6.4.2.1. By Drug Class

                14.6.4.2.2. By Distribution Channel

15. East Asia Polycystic Ovary Syndrome (PCOS) Treatment Market Analysis 2015–2021 and Forecast 2022–2032

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2021

    15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032

        15.3.1. By Country

            15.3.1.1. China

            15.3.1.2. Japan

            15.3.1.3. South Korea

        15.3.2. By Drug Class

        15.3.3. By Distribution Channel

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Drug Class

        15.4.3. By Distribution Channel

    15.5. Drivers and Restraints – Impact Analysis

    15.6. Country Level Analysis & Forecast

        15.6.1. China Polycystic Ovary Syndrome (PCOS) Treatment Market

            15.6.1.1. Introduction

            15.6.1.2. Market Analysis and Forecast by Market Taxonomy

                15.6.1.2.1. By Drug Class

                15.6.1.2.2. By Distribution Channel

        15.6.2. Japan Polycystic Ovary Syndrome (PCOS) Treatment Market

            15.6.2.1. Introduction

            15.6.2.2. Market Analysis and Forecast by Market Taxonomy

                15.6.2.2.1. By Drug Class

                15.6.2.2.2. By Distribution Channel

        15.6.3. South Korea Polycystic Ovary Syndrome (PCOS) Treatment Market

            15.6.3.1. Introduction

            15.6.3.2. Market Analysis and Forecast by Market Taxonomy

                15.6.3.2.1. By Drug Class

                15.6.3.2.2. By Distribution Channel

16. Oceania Polycystic Ovary Syndrome (PCOS) Treatment Market Analysis 2015–2021 and Forecast 2022–2032

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2021

    16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032

        16.3.1. By Country

            16.3.1.1. Australia

            16.3.1.2. New Zealand

        16.3.2. By Drug Class

        16.3.3. By Distribution Channel

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Drug Class

        16.4.3. By Distribution Channel

    16.5. Drivers and Restraints – Impact Analysis

        16.5.1. By Country

        16.5.2. By Drug Class

        16.5.3. By Distribution Channel

    16.6. Country Level Analysis & Forecast

        16.6.1. Australia Polycystic Ovary Syndrome (PCOS) Treatment Market

            16.6.1.1. Introduction

            16.6.1.2. Market Analysis and Forecast by Market Taxonomy

                16.6.1.2.1. By Drug Class

                16.6.1.2.2. By Distribution Channel

        16.6.2. New Zealand Polycystic Ovary Syndrome (PCOS) Treatment Market

            16.6.2.1. Introduction

            16.6.2.2. Market Analysis and Forecast by Market Taxonomy

                16.6.2.2.1. By Drug Class

                16.6.2.2.2. By Distribution Channel

17. Middle East and Africa (MEA) Polycystic Ovary Syndrome (PCOS) Treatment Market  Analysis 2015–2021 and Forecast 2022–2032

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2021

    17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032

        17.3.1. By Country

            17.3.1.1. GCC Countries

            17.3.1.2. Turkey

            17.3.1.3. North Africa

            17.3.1.4. South Africa

            17.3.1.5. Rest of Middle East and Africa

        17.3.2. By Drug Class

        17.3.3. By Distribution Channel

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Drug Class

        17.4.3. By Distribution Channel

    17.5. Drivers and Restraints – Impact Analysis

        17.5.1. By Country

        17.5.2. By Drug Class

        17.5.3. By Distribution Channel

    17.6. Country Level Analysis & Forecast

        17.6.1. GCC Countries Polycystic Ovary Syndrome (PCOS) Treatment Market

            17.6.1.1. Introduction

            17.6.1.2. Market Analysis and Forecast by Market Taxonomy

                17.6.1.2.1. By Drug Class

                17.6.1.2.2. By Distribution Channel

        17.6.2. Israel Polycystic Ovary Syndrome (PCOS) Treatment Market

            17.6.2.1. Introduction

            17.6.2.2. Market Analysis and Forecast by Market Taxonomy

                17.6.2.2.1. By Drug Class

                17.6.2.2.2. By Distribution Channel

        17.6.3. Turkey Polycystic Ovary Syndrome (PCOS) Treatment Market

            17.6.3.1. Introduction

            17.6.3.2. Market Analysis and Forecast by Market Taxonomy

                17.6.3.2.1. By Drug Class

                17.6.3.2.2. By Distribution Channel

        17.6.4. South Africa Polycystic Ovary Syndrome (PCOS) Treatment Market

            17.6.4.1. Introduction

            17.6.4.2. Market Analysis and Forecast by Market Taxonomy

                17.6.4.2.1. By Drug Class

                17.6.4.2.2. By Distribution Channel

        17.6.5. North Africa Polycystic Ovary Syndrome (PCOS) Treatment Market

            17.6.5.1. Introduction

            17.6.5.2. Market Analysis and Forecast by Market Taxonomy

                17.6.5.2.1. By Drug Class

                17.6.5.2.2. By Distribution Channel

18. Competition Analysis

    18.1. Competition Dashboard

    18.2. Competition Deep Dive (Tentative List)

        18.2.1. Novartis AG

            18.2.1.1. Overview

            18.2.1.2. Product Portfolio

            18.2.1.3. Key Financials

            18.2.1.4. SWOT Analysis

            18.2.1.5. Sales Footprint

            18.2.1.6. Strategy Overview

            18.2.1.7. Key Developments

        18.2.2. Sanofi.

            18.2.2.1. Overview

            18.2.2.2. Product Portfolio

            18.2.2.3. Key Financials

            18.2.2.4. SWOT Analysis

            18.2.2.5. Sales Footprint

            18.2.2.6. Strategy Overview

            18.2.2.7. Key Developments

        18.2.3. Teva Pharmaceutical Industries Limited

            18.2.3.1. Overview

            18.2.3.2. Product Portfolio

            18.2.3.3. Key Financials

            18.2.3.4. SWOT Analysis

            18.2.3.5. Sales Footprint

            18.2.3.6. Strategy Overview

            18.2.3.7. Key Developments

        18.2.4. Merck & Co., Inc. (Merck group)

            18.2.4.1. Overview

            18.2.4.2. Product Portfolio

            18.2.4.3. Key Financials

            18.2.4.4. SWOT Analysis

            18.2.4.5. Sales Footprint

            18.2.4.6. Strategy Overview

            18.2.4.7. Key Developments

        18.2.5. AstraZeneca plc.

            18.2.5.1. Overview

            18.2.5.2. Product Portfolio

            18.2.5.3. Key Financials

            18.2.5.4. SWOT Analysis

            18.2.5.5. Sales Footprint

            18.2.5.6. Strategy Overview

            18.2.5.7. Key Developments

        18.2.6. Bayer AG

            18.2.6.1. Overview

            18.2.6.2. Product Portfolio

            18.2.6.3. Key Financials

            18.2.6.4. SWOT Analysis

            18.2.6.5. Sales Footprint

            18.2.6.6. Strategy Overview

            18.2.6.7. Key Developments

        18.2.7. Abbott

            18.2.7.1. Overview

            18.2.7.2. Product Portfolio

            18.2.7.3. Key Financials

            18.2.7.4. SWOT Analysis

            18.2.7.5. Sales Footprint

            18.2.7.6. Strategy Overview

            18.2.7.7. Key Developments

        18.2.8. Pfizer, Inc.

            18.2.8.1. Overview

            18.2.8.2. Product Portfolio

            18.2.8.3. Key Financials

            18.2.8.4. SWOT Analysis

            18.2.8.5. Sales Footprint

            18.2.8.6. Strategy Overview

            18.2.8.7. Key Developments

        18.2.9. Bristol-Myer Squibb Company

            18.2.9.1. Overview

            18.2.9.2. Product Portfolio

            18.2.9.3. Key Financials

            18.2.9.4. SWOT Analysis

            18.2.9.5. Sales Footprint

            18.2.9.6. Strategy Overview

            18.2.9.7. Key Developments

        18.2.10. Ferring Pharmaceuticals, Inc.

            18.2.10.1. Overview

            18.2.10.2. Product Portfolio

            18.2.10.3. Key Financials

            18.2.10.4. SWOT Analysis

            18.2.10.5. Sales Footprint

            18.2.10.6. Strategy Overview

            18.2.10.7. Key Developments

        18.2.11. Johnson and Johnson

            18.2.11.1. Overview

            18.2.11.2. Product Portfolio

            18.2.11.3. Key Financials

            18.2.11.4. SWOT Analysis

            18.2.11.5. Sales Footprint

            18.2.11.6. Strategy Overview

            18.2.11.7. Key Developments

        18.2.12. Mylan N.V.

            18.2.12.1. Overview

            18.2.12.2. Product Portfolio

            18.2.12.3. Key Financials

            18.2.12.4. SWOT Analysis

            18.2.12.5. Sales Footprint

            18.2.12.6. Strategy Overview

            18.2.12.7. Key Developments

        18.2.13. Allergan plc.

            18.2.13.1. Overview

            18.2.13.2. Product Portfolio

            18.2.13.3. Key Financials

            18.2.13.4. SWOT Analysis

            18.2.13.5. Sales Footprint

            18.2.13.6. Strategy Overview

            18.2.13.7. Key Developments

        18.2.14. GlaxoSmithKline

            18.2.14.1. Overview

            18.2.14.2. Product Portfolio

            18.2.14.3. Key Financials

            18.2.14.4. SWOT Analysis

            18.2.14.5. Sales Footprint

            18.2.14.6. Strategy Overview

            18.2.14.7. Key Developments

        18.2.15. Lupin Pharmaceuticals

            18.2.15.1. Overview

            18.2.15.2. Product Portfolio

            18.2.15.3. Key Financials

            18.2.15.4. SWOT Analysis

            18.2.15.5. Sales Footprint

            18.2.15.6. Strategy Overview

            18.2.15.7. Key Developments

        18.2.16. AbbVie

            18.2.16.1. Overview

            18.2.16.2. Product Portfolio

            18.2.16.3. Key Financials

            18.2.16.4. SWOT Analysis

            18.2.16.5. Sales Footprint

            18.2.16.6. Strategy Overview

            18.2.16.7. Key Developments

        18.2.17. Takeda

            18.2.17.1. Overview

            18.2.17.2. Product Portfolio

            18.2.17.3. Key Financials

            18.2.17.4. SWOT Analysis

            18.2.17.5. Sales Footprint

            18.2.17.6. Strategy Overview

            18.2.17.7. Key Developments

        18.2.18. BIOCAD Global

            18.2.18.1. Overview

            18.2.18.2. Product Portfolio

            18.2.18.3. Key Financials

            18.2.18.4. SWOT Analysis

            18.2.18.5. Sales Footprint

            18.2.18.6. Strategy Overview

            18.2.18.7. Key Developments

        18.2.19. Blairex Laboratories Inc.

            18.2.19.1. Overview

            18.2.19.2. Product Portfolio

            18.2.19.3. Key Financials

            18.2.19.4. SWOT Analysis

            18.2.19.5. Sales Footprint

            18.2.19.6. Strategy Overview

            18.2.19.7. Key Developments

        18.2.20. Agile Therapeutics

            18.2.20.1. Overview

            18.2.20.2. Product Portfolio

            18.2.20.3. Key Financials

            18.2.20.4. SWOT Analysis

            18.2.20.5. Sales Footprint

            18.2.20.6. Strategy Overview

            18.2.20.7. Key Developments




• 英文レポート名:Market Study on Polycystic Ovary Syndrome (PCOS) Treatment: Market Driven by Rising Prevalence of Endocrine Diseases
• 日本語訳:多嚢胞性卵巣症候群(PCOS)治療の世界市場研究
• レポートコード:MRC2301E004お問い合わせ(見積依頼・ご注文・質問)